Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

merck sharp & dohme corp. - polisacarido (aislado de streptococcus pneumoniae): 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, 33f - polisacarido (aislado de streptococcus pneumoniae): 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, 33f....25 µg (0.0005 %) de cada policasarido.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck sharp and dohme llc, united states - pneumococcal (streptococcus pneumoniae) polysaccharide (serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f, 33f) - solution for injection - 50 µ/ml,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck sharp and dohme llc, united states - pneumococcal (streptococcus pneumoniae) polysaccharide (serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f, 33f) - solution for injection - 50 µ/ml,

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - streptococcus pneumoniae - solution for injection - streptococcus pneumoniae 25 µg - vaccines

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - streptococcus pneumoniae type 1 capsular polysaccharide antigen 25 ug in 0.5 ml - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - streptococcus pneumoniae serotype 9n capsular polysaccharide; streptococcus pneumoniae serotype 9v capsular polysaccharide; streptococcus pneumoniae serotype 10a capsular polysaccharide; streptococcus pneumoniae serotype 11a capsular polysaccharide; streptococcus pneumoniae serotype 12f capsular polysaccharide; streptococcus pneumoniae serotype 14 capsular polysaccharide; streptococcus pneumoniae serotype 15b capsular polysaccharide; streptococcus pneumoniae serotype 17a or 17f capsular polysaccharide; streptococcus pneumoniae serotype 18c capsular polysaccharide; streptococcus pneumoniae serotype 19f capsular polysaccharide; streptococcus pneumoniae serotype 19a capsular polysaccharide; streptococcus pneumoniae serotype 20 capsular polysaccharide; streptococcus pneumoniae serotype 22f capsular polysaccharide; streptococcus pneumoniae serotype 23f capsular polysaccharide; streptococcus pneumoniae serotype 33f capsular polysaccharide; streptococcus pneumoniae serotype 1 capsular polysaccharide; streptococcus pneumoniae serotype 2 capsular polysaccharide; streptococcus pneumoniae serotype 3 capsular polysaccharide; streptococcus pneumoniae serotype 4 capsular polysaccharide; streptococcus pneumoniae serotype 5 capsular polysaccharide; streptococcus pneumoniae serotype 6b capsular polysaccharide; streptococcus pneumoniae serotype 7f capsular polysaccharide; streptococcus pneumoniae serotype 8 capsular polysaccharide - solution for injection

United States - English - NLM (National Library of Medicine)

a-s medication solutions - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of

Israel - English - Ministry of Health

medici medical ltd, israel - streptococcus pneumoniae - solution for injection - streptococcus pneumoniae 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - prevention of pneumococcal infections, particularly of the respiratory type, in patients presenting an increased risk over the age of 2 years.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.